PALO ALTO, Calif., June 11 /PRNewswire-FirstCall/ -- Jazz
Pharmaceuticals, Inc. (Nasdaq: JAZZ) today announced the filing of a
universal shelf registration statement with the U.S. Securities and
Exchange Commission (SEC). If and when the universal shelf registration
statement has been declared effective by the SEC, Jazz Pharmaceuticals may
from time-to-time offer and sell up to an aggregate of $100 million of its
common stock, preferred stock, warrants and/or debt securities, either
individually or in units. The securities may be offered in separate series,
in amounts, at prices and upon terms to be established at the time of each
offering. Any offers, solicitations of offers to buy or sales of securities
will only be made pursuant to the universal shelf registration statement
filed with and declared effective by the SEC, including the prospectus and
related prospectus supplement.

The universal shelf registration statement is intended to provide Jazz
Pharmaceuticals with flexibility to raise funds from the offering of its
securities in one or more offerings, subject to market conditions and the
company's capital needs.

Jazz Pharmaceuticals also announced the filing of two resale
registration statements on Form S-3 to register: (i) the resale of shares
of the company's common stock issuable upon the exercise of outstanding
warrants issued in connection with Jazz Pharmaceuticals' private placement
of senior secured notes completed in March 2008, as well as shares of the
company's common stock issuable upon the exercise of warrants that may be
issued in the event of additional issuances of senior secured notes under
the same facility; and (ii) the resale of shares of the company's common
stock that may be issued upon the company's election to draw down funds
pursuant to the committed equity financing facility entered into with
Kingsbridge Capital Limited in May 2008, as well as the common stock
issuable upon exercise of an outstanding warrant issued to Kingsbridge in
connection with the transaction. If and when declared effective by the SEC,
the resale registration statements will allow the selling securityholders
named therein to publicly resell shares of the company's common stock
issuable pursuant to the committed equity financing facility and upon the
exercise of the above-referenced warrants, as applicable. Written
prospectuses, when available, may be obtained from Jazz Pharmaceuticals at
3180 Porter Drive, Palo Alto, California 94304, Attention: Investor
Relations.

The registration statements relating to these securities have been
filed with the SEC but have not yet become effective. These securities may
not be sold, nor may offers to buy be accepted prior to the time the
applicable registration statement becomes effective. This press release
shall not constitute an offer to sell, or the solicitation of an offer to
buy, nor shall there be any sale of the securities in any state in which
such offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state.

About Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals is a specialty pharmaceutical company focused on
identifying, developing and commercializing innovative products to meet
unmet medical needs in neurology and psychiatry. For further information
see http://www.JazzPharmaceuticals.com.

This press release contains forward-looking statements, including, but
not limited to, statements related to the offering of securities by Jazz
Pharmaceuticals and the issuance of additional debt under an existing
facility. These forward-looking statements are based on the company's
current expectations and inherently involve significant risks and
uncertainties. Jazz Pharmaceuticals' actual results and the timing of
events could differ materially from those anticipated in such forward
looking statements as a result of these risks and uncertainties, which
include, without limitation, risks related to Jazz Pharmaceuticals' need
for additional funds. These and other risk factors are discussed under the
heading "Risk Factors" in the two resale registration statements filed on
Form S-3 by Jazz Pharmaceuticals with the Securities and Exchange
Commission on June 11, 2008. Jazz Pharmaceuticals undertakes no duty or
obligation to update any forward-looking statements contained in this
release as a result of new information, future events or changes in its
expectations.

(Date:12/8/2016)... Eurofins announces the appointment of Sean Murray , National Division ... Mr. Murray will bring valuable expertise to the ... leading international business teams. As the National Division Leader, he will ... status as the global leader in bio-analytical testing services. ... , , ...

(Date:12/8/2016)... Dec. 8, 2016 Anaconda BioMed S.L., a pre-clinical ... the next generation neuro-thrombectomy system for the treatment of ... G. Jovin, MD to join its Scientific Advisory Board ... strategic network of scientific and clinical experts to Anaconda ... the ANCD BRAIN ® to its clinical phase. ...

(Date:11/21/2016)... , Nov. 21, 2016 Neurotechnology ... object recognition technologies, today announced that the MegaMatcher ... cards was submitted for the NIST Minutiae ... passed all the mandatory steps of the evaluation ... is a continuing test of fingerprint templates used ...